<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Polyhydramnios: Etiology, diagnosis, and management in singleton gestations
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Polyhydramnios: Etiology, diagnosis, and management in singleton gestations
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Polyhydramnios: Etiology, diagnosis, and management in singleton gestations
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ron Beloosesky, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael G Ross, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynn L Simpson, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Deborah Levine, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 10, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polyhydramnios (also known as hydramnios) refers to an excessive volume of amniotic fluid. It should be suspected clinically when uterine size is large for gestational age (fundal height [cm] that exceeds the weeks of gestation by &gt;3). Prenatal diagnosis is based upon noninvasive sonographic documentation of excessive amniotic fluid volume (AFV) by a quantitative technique, such as amniotic fluid index (AFI) ≥24 cm or single deepest pocket (SDP) ≥8 cm.
        </p>
        <p>
         Polyhydramnios can be idiopathic or related to a variety of maternal and fetal disorders [
         <a href="#rid1">
          1-3
         </a>
         ]. Potential consequences include increased risks for preterm birth, fetal malposition, placental abruption and/or cord prolapse.
        </p>
        <p>
         This topic will discuss issues related to polyhydramnios in singleton gestations. Methods of AFV assessment are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/462.html" rel="external">
          "Assessment of amniotic fluid volume"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          INCIDENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of polyhydramnios in a general obstetric population generally ranges from 1 to 2 percent [
         <a href="#rid4">
          4-9
         </a>
         ]. Reported rates are highly influenced by the gestational age at the time of the ultrasound examination (higher preterm, lower postterm), the population studied (low or high risk, screening or indicated ultrasound examination, antepartum or intrapartum), and variations in diagnostic criteria (use of amniotic fluid index [AFI] versus single deepest pocket [SDP]).
        </p>
        <p>
         In a series of over 93,000 singleton pregnancies delivering over six years at a single hospital, polyhydramnios was diagnosed during antepartum sonography in 0.7 percent and was described as mild, moderate, or severe in 66, 22, and 12 percent of cases, respectively [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The volume of amniotic fluid reflects the balance between fluid production and movement of fluid out of the amniotic sac. The most common mechanisms for polyhydramnios are decreased fetal swallowing and increased urination [
         <a href="#rid10">
          10-12
         </a>
         ].
        </p>
        <p>
         Homeostatic mechanisms, such as intramembranous absorption (transfer of amniotic fluid across the amnion into the fetal circulation), work to maintain amniotic fluid volume (AFV); these mechanisms appear to be more successful in preventing polyhydramnios than in preventing oligohydramnios. (See
         <a class="medical medical_review" href="/z/d/html/2283.html" rel="external">
          "Physiology of amniotic fluid volume regulation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CONDITIONS ASSOCIATED WITH POLYHYDRAMNIOS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polyhydramnios may be idiopathic or associated with a variety of disorders  (
         <a class="graphic graphic_table graphicRef130889" href="/z/d/graphic/130889.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Fetal anomalies (often associated with an underlying genetic abnormality or syndrome) are the most common conditions associated with severe polyhydramnios, while maternal diabetes, multiple gestation, and idiopathic factors are more often associated with milder cases.
        </p>
        <p>
         Sometimes, multiple pathways are involved in production of excess amniotic fluid. For example, congenital mesoblastic nephroma is associated with polyhydramnios in approximately 70 percent of cases and contributes to the high rate (25 percent) of preterm birth. The increased amniotic fluid may be attributed to increased urine production due to renal hyperperfusion, decreased gastrointestinal absorption due to bowel compression, or tumor secretion of prostaglandins leading to hypercalcemia-induced polyuria [
         <a href="#rid13">
          13
         </a>
         ]. Rarely, cardiac failure and hydrops occur [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1154032175">
         <span class="h2">
          Idiopathic cases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 40 percent of polyhydramnios is idiopathic [
         <a href="#rid15">
          15
         </a>
         ]. After birth, however, an abnormality is diagnosed in up to 25 percent of cases considered idiopathic prenatally [
         <a href="#rid15">
          15-18
         </a>
         ]. Fetal anemia, Bartter syndrome, infection, and neuromuscular disorders account for some cases considered idiopathic prenatally, and should be considered in the differential diagnosis if a structural abnormality and maternal diabetes are excluded, although Bartter syndrome and neuromuscular diseases are quite rare, and infection (TORCH [toxoplasmosis, other, rubella, cytomegalovirus, and herpes simplex virus], parvovirus) is rarely associated with isolated polyhydramnios. In a retrospective observational study of 294 singleton pregnancies with polyhydramnios and serum screening for TORCH and parvovirus B19 infections, only two patients tested positive for parvovirus infection and only one for toxoplasmosis infection [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3260243709">
         <span class="h3">
          Recurrence
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a study of over 2.7 million singleton births in the Medical Birth Registry of Norway (1967 to 2017), individuals with idiopathic polyhydramnios in their first pregnancy had a 6.6-fold increase in odds of idiopathic polyhydramnios in their second pregnancy compared with those without idiopathic polyhydramnios in their first pregnancy [
         <a href="#rid20">
          20
         </a>
         ]. The odds increased 12.6-fold in the third pregnancy after two previously affected pregnancies but were less if only one of the first two pregnancies had idiopathic polyhydramnios.
        </p>
        <p class="headingAnchor" id="H828947198">
         <span class="h2">
          Fetal anomalies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fetal anomalies account for approximately one-third of singleton pregnancies with polyhydramnios [
         <a href="#rid15">
          15
         </a>
         ]. The most common anomalies interfere with fetal swallowing and/or absorption of fluid [
         <a href="#rid21">
          21,22
         </a>
         ]. Obstruction of the gastrointestinal tract may be primary (eg, duodenal, esophageal, or upper intestinal atresia) or secondary (eg, massive unilateral dysplastic kidneys, large thoracic mass, diaphragmatic hernia).
        </p>
        <p>
         Anomalies in most other organ systems have been associated with polyhydramnios, but are less common and can involve other mechanisms.
        </p>
        <p class="headingAnchor" id="H1778603142">
         <span class="h2">
          Maternal diabetes mellitus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maternal diabetes accounts for 8 to 25 percent of pregnancies with polyhydramnios [
         <a href="#rid23">
          23
         </a>
         ]. The rates of polyhydramnios in patients with versus without diabetes were 10.5 and 3.8 percent, respectively, when diagnosed by amniotic fluid index (AFI) in a large retrospective study [
         <a href="#rid24">
          24
         </a>
         ]. The rate varied, in part, by type of diabetes: gestational A1 (5.4 percent), gestational A2 (13.4 percent), type 1 (21.2 percent), and type 2 (15.3 percent). All of these rates were higher when diagnosed by single deepest pocket (SDP).
        </p>
        <p>
         The mechanism for polyhydramnios in pregnancies complicated by maternal diabetes is unclear, though it is believed that fetal hyperglycemia-induced polyuria (osmotic diuresis) is the most likely etiology. This conclusion is supported by the observation that polyhydramnios is often associated with high maternal glycated hemoglobin (A1C) levels and fetal macrosomia [
         <a href="#rid25">
          25,26
         </a>
         ]. Thus, the increasing incidence of polyhydramnios from progression of diabetes A1, to A2, to type 2, to type 1 is consistent with increasing maternal (and thus fetal) serum glucose levels. Decreased fetal swallowing or an imbalance in water movement between the maternal and fetal compartments in diabetic pregnancies are other possible mechanisms.
        </p>
        <p>
         A retrospective study including 1545 patients with polyhydramnios found that only 8.5 percent of cases could be attributed to diabetes, and those patients usually had mild polyhydramnios (defined as an AFI 26.0 to 35.9 cm) [
         <a href="#rid23">
          23
         </a>
         ]. Other researchers have demonstrated that pregnancies with normal glucose tolerance tests that develop polyhydramnios and accelerated fetal growth are at higher risk for maternal and neonatal complications, while isolated polyhydramnios without accelerated growth increases the risk for birth complications but not neonatal morbidity [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4139349697">
         <span class="h2">
          Fetal growth restriction
         </span>
         <span class="headingEndMark">
          —
         </span>
         When
         <strong>
         </strong>
         combined with polyhydramnios, fetal growth restriction (FGR) is associated with high morbidity and mortality. In a study of 153 pregnancies with FGR and polyhydramnios, four potential etiological groups were identified: chromosomal anomalies (41.8 percent, n = 64), complex malformation syndromes (24.1 percent, n = 37), isolated malformations (15.7 percent, n = 24), musculoskeletal disorders (9.2 percent, n = 14); another 9.2 percent (n = 14) had no abnormalities detected prenatally [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2143381628">
         <span class="h2">
          Twin-twin transfusion syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple gestation accounts for up to 10 percent of polyhydramnios. In monochorionic multiple gestation, polyhydramnios/oligohydramnios sequence is most suggestive of TTTS. (See
         <a class="medical medical_review" href="/z/d/html/6789.html" rel="external">
          "Twin-twin transfusion syndrome: Screening, prevalence, pathophysiology, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H444115671">
         <span class="h2">
          Aneuploidy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aneuploidy is an uncommon cause of polyhydramnios [
         <a href="#rid19">
          19
         </a>
         ]. The combination of fetal growth restriction and polyhydramnios is suggestive of trisomy 18; other sonographic markers of trisomy 18 are typically present. Excess amniotic fluid in this syndrome may be related to difficulty swallowing or to intestinal abnormalities. (See
         <a class="medical medical_review" href="/z/d/html/447.html" rel="external">
          "Sonographic findings associated with fetal aneuploidy", section on 'Trisomy 18 (Edward syndrome)'
         </a>
         .)
        </p>
        <p>
         Other aneuploidies have also been associated with polyhydramnios, most commonly trisomy 21, likely related to cases with duodenal atresia. (See
         <a class="medical medical_review" href="/z/d/html/447.html" rel="external">
          "Sonographic findings associated with fetal aneuploidy", section on 'Trisomy 21 (Down syndrome)'
         </a>
         .)
        </p>
        <p>
         In a retrospective cohort of 623 singleton pregnancies with isolated polyhydramnios, 3.1 percent (19 out of 623) were associated with clinically significant chromosomal microarray (CMA) aberrations compared with 1.4 percent of control cases (78 out of 5541) with normal ultrasound [
         <a href="#rid29">
          29
         </a>
         ]. However, the risk for abnormal CMA results in the 158 cases with mild polyhydramnios (AFI 25 to 29.9, or maximal vertical pocket 8 to 11.9 cm) was similar to that from pregnancies with normal ultrasound. Among 119 cases with nonisolated polyhydramnios, abnormal CMA findings were noted in 6.7 percent of cases and were primarily karyotype-detectable. The most frequent associated anomalies involved the cardiovascular system (26.1 percent) and brain (15.1 percent).
        </p>
        <p class="headingAnchor" id="H1645697087">
         <span class="h2">
          High cardiac output states
         </span>
         <span class="headingEndMark">
          —
         </span>
         High fetal cardiac output states can lead to increased fetal urine production, but are uncommon [
         <a href="#rid19">
          19
         </a>
         ]. Fetal anemia is a common cause of a high-output state and may be due to alloimmunization, parvovirus B19 infection, a large or chronic fetomaternal hemorrhage, alpha-thalassemia, hemolysis secondary to glucose-6-phosphate dehydrogenase deficiency, and other disorders [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         High-output states can also be caused by arteriovenous shunting (eg, sacrococcygeal teratoma, TTTS, chorioangioma) and tachyarrhythmias.
        </p>
        <p class="headingAnchor" id="H3248743631">
         <span class="h2">
          Neuromuscular disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fetal neuromuscular disorders, such as anencephaly and myotonic dystrophy, are rare and generally cause polyhydramnios by interfering with swallowing [
         <a href="#rid31">
          31-35
         </a>
         ]. In a retrospective study of the prenatal sonographic manifestation of congenital hypotonia, polyhydramnios was the most prominent sonographic sign, observed in 16 of 25 cases (64 percent) beginning in the late second trimester, while absent fetal tone on the last biophysical scan was observed in only two of 25 cases (8 percent) [
         <a href="#rid36">
          36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5147.html" rel="external">
          "Myotonic dystrophy: Etiology, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16869.html" rel="external">
          "Anencephaly"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6148.html" rel="external">
          "Approach to the infant with hypotonia and weakness"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6151.html" rel="external">
          "Overview of peripheral nerve and muscle disorders causing hypotonia in the newborn"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H240225839">
         <span class="h2">
          Bartter syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common antenatal type of Bartter syndrome is a rare autosomal recessive tubular disorder associated with intrauterine presentation of renal tubular hypokalemic alkalosis. As a result, the fetus develops polyuria and subsequent polyhydramnios between 24 and 30 weeks of gestation. Infants exhibit postnatal polyuria and persistent renal salt wasting, requiring lifelong treatment.
        </p>
        <p>
         A severe but transient form of antenatal Bartter syndrome has been attributed to mutations in
         <em>
          MAGED2,
         </em>
         which maps to the X chromosome and appears to be essential for fetal renal salt reabsorption and maintenance of normal amniotic fluid homeostasis [
         <a href="#rid37">
          37
         </a>
         ]. This X-linked disorder has very early onset of severe polyhydramnios (median 19 to 20 weeks of gestation), often resulting in preterm birth (median gestational age 22 to 34 weeks), but signs and symptoms of renal dysfunction resolve spontaneously postnatally. (See
         <a class="medical medical_review" href="/z/d/html/2344.html" rel="external">
          "Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3735180920">
         <span class="h2">
          Overgrowth syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         In cases of excessive growth for gestational age associated with polyhydramnios, omphalocele, placentomegaly, or macroglossia, Beckwith-Wiedemann syndrome or one of the other overgrowth syndromes should be considered [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13555.html" rel="external">
          "Beckwith-Wiedemann syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4790845">
         <span class="h1">
          CLINICAL FINDINGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polyhydramnios presents with a uterine size that is large for gestational age (fundal height [cm] that exceeds the weeks of gestation by &gt;3) or as an incidental finding on a prenatal ultrasound examination.
        </p>
        <p>
         The increase in amniotic fluid volume (AFV) is usually asymptomatic; however, persistent shortness of breath, uterine irritability and contractions, and abdominal discomfort can occur with severe uterine distention. Symptoms may be related to mechanical factors from a very large uterus and to high amniotic fluid pressure [
         <a href="#rid39">
          39,40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of polyhydramnios is based upon sonographic visualization of increased amniotic fluid volume (AFV). We agree with recommendations from a consensus panel at a fetal imaging workshop [
         <a href="#rid41">
          41
         </a>
         ] and endorsed by the Society for Maternal-Fetal Medicine [
         <a href="#rid42">
          42
         </a>
         ] that suggested using either of the following thresholds for diagnosing polyhydramnios:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Single deepest pocket (SDP) ≥8 cm
         <strong>
          or
         </strong>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Amniotic fluid index (AFI) ≥24 cm
        </p>
        <p>
        </p>
        <p>
         SDP and AFI can also be used to classify polyhydramnios as mild, moderate, or severe  (
         <a class="graphic graphic_table graphicRef89351" href="/z/d/graphic/89351.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Although a qualitative assessment of mild, moderate, or severe polyhydramnios can be made initially, we use a quantitative approach because it provides a measurement that can be compared over serial examinations. Both SDP and AFI are the accepted standards for diagnosis and clinical management. Although these tests perform relatively poorly against quantitative measurements using dye dilution (research studies), they have been associated with an increased risk of adverse outcome and thus have clinical utility.
        </p>
        <p>
         It appears that the SDP overdiagnoses polyhydramnios as compared with the AFI. Of note, however, AFI may overdiagnose oligohydramnios when compared with SDP [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          POSTDIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following evaluation is most appropriate for nonhydropic singletons and dichorionic twins. In monochorionic twins with polyhydramnios/oligohydramnios sequence, twin-twin transfusion syndrome is the most likely diagnosis and is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6789.html" rel="external">
          "Twin-twin transfusion syndrome: Screening, prevalence, pathophysiology, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6793.html" rel="external">
          "Twin-twin transfusion syndrome: Management and outcome"
         </a>
         .)
        </p>
        <p>
         Approach to determining the etiology of polyhydramnios:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obtain a detailed
         </strong>
         <strong>
          medical history
         </strong>
         to evaluate for heritable diseases associated with polyhydramnios. For example, arthrogryposis often presents in the second trimester with polyhydramnios and multiple congenital contractures, which should be identified by ultrasound. More than 150 genetic syndromes are associated with arthrogryposis; most cases are recessive inheritance or new pathogenic variants. If suspected, the patient should be referred to a genetics specialist for three-generation pedigree and parental examination.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients in whom the personal/family history suggests a hereditary anemia (eg, alpha-thalassemia) or inborn error of metabolism, testing for the relevant disorder is indicated. (See
         <a class="medical medical_review" href="/z/d/html/445.html" rel="external">
          "Hemoglobinopathy: Screening and counseling in the reproductive setting and fetal diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7111.html" rel="external">
          "Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency", section on 'Pregnancy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/17216.html" rel="external">
          "Inborn errors of metabolism: Identifying the specific disorder"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluate for fetal hydrops
         </strong>
         – If polyhydramnios is accompanied by hydrops, evaluation for a nonimmune or immune etiology is the priority. Fetal anemia is a common cause of hydrops and has both immune and nonimmune etiologies. (See
         <a class="medical medical_review" href="/z/d/html/6794.html" rel="external">
          "Nonimmune hydrops fetalis", section on 'Postdiagnostic evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6820.html" rel="external">
          "RhD alloimmunization in pregnancy: Overview", section on 'Fetal/neonatal consequences of alloimmunization'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluate for fetal anomalies
         </strong>
         – A detailed sonographic evaluation should be performed to look for fetal anomalies. The likelihood of identifying the etiology of polyhydramnios prenatally correlates with the severity of fluid accumulation. In one series, an etiology was determined in only 17 percent of pregnancies with mild polyhydramnios but in 91 percent of those with moderate or severe amniotic fluid accumulation [
         <a href="#rid4">
          4
         </a>
         ]. In another series, the frequency of an anomalous infant in the setting of mild, moderate, and severe polyhydramnios was 8, 12, and 31 percent, respectively [
         <a href="#rid5">
          5
         </a>
         ]. Overall, 80 percent of anomalous infants were detected prenatally. Anomalies most often missed included esophageal atresia with a tracheoesophageal fistula, cardiac septal defects, and cleft palate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In cases of polyhydramnios with suspicion of esophageal atresia (small or nonvisualizable fetal stomach bubble), elevated levels of amniotic fluid gamma-glutamyl transpeptidase and alpha-fetoprotein are suggestive of the diagnosis and can be performed at the time of amniocentesis for genetic studies [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Measure middle cerebral artery (MCA) post systolic velocity (PSV)
         </strong>
         – We measure the MCA-PSV in the initial evaluation of all cases of idiopathic polyhydramnios before 35 weeks of gestation, even in the absence of hydrops. Although fetal hydrops precedes polyhydramnios in the vast majority of polyhydramnios cases associated with fetal anemia, we have encountered cases of fetal anemia in which polyhydramnios preceded the appearance of hydrops.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         MCA-PSV performs well from 25 to 35 weeks of gestation. Doppler findings suggestive of moderate and severe fetal anemia (MCA-PSV ≥1.5 multiples of the median [MoM]) had a false-positive rate of 12 percent in a study of 111 fetuses up to 36 weeks of gestation at risk for anemia and in whom 17 percent had severe anemia without hydrops (amniotic fluid volume [AFV] was not described) [
         <a href="#rid45">
          45
         </a>
         ]. The false-positive rate is higher after 35 weeks [
         <a href="#rid46">
          46
         </a>
         ] and lower if a threshold of ≥1.29 MoMs is used [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If MCA-PSV is ≥1.5 multiples of the median, work-up for immune and nonimmune causes of fetal anemia should be performed. (See
         <a class="medical medical_review" href="/z/d/html/6794.html" rel="external">
          "Nonimmune hydrops fetalis", section on 'Postdiagnostic evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Offer genetic counseling and fetal genetic studies
         </strong>
         – We suggest genetic counseling and offering amniocentesis for fetal microarray in pregnancies with a congenital anomaly or severe polyhydramnios (all cases, even if apparently isolated), especially if the results will affect pregnancy management. Whether genetic studies should be offered in the absence of fetal anomalies or severe polyhydramnios is controversial as the likelihood of chromosomal abnormality is low in this setting [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When a fetal anomaly is present, patients are offered microarray because of the increased risk of chromosomal abnormalities in this setting. In cases of polyhydramnios associated with anomalies not known to be associated with an increased risk of chromosomal abnormalities (eg, jejunal atresia), referral to a maternal-fetal medicine specialist and/or genetic counselor can help with shared decision-making regarding microarray or other genetic examinations. (See
         <a class="medical medical_review" href="/z/d/html/104101.html" rel="external">
          "Prenatal genetic evaluation of the fetus with anomalies or soft markers"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When severe polyhydramnios is present, we offer microarray because of data showing increased frequencies of congenital anomalies [
         <a href="#rid5">
          5,48
         </a>
         ] and genetic abnormalities with increasing degrees of polyhydramnios. In a series of 249 singleton pregnancies with mild, moderate, or severe isolated polyhydramnios referred for amniocentesis, clinically significant microarray aberrations were detected in 5 of 91 patients with moderate or severe polyhydramnios (5.5 percent), a higher rate than that in patients with mild polyhydramnios (4 out of 158, 2.5 percent) or in a control population (1.4 percent); the rates in the latter two groups were not significantly different [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Role of gene sequencing
         </strong>
         – In cases of severe polyhydramnios with a fetal anomaly and a normal microarray, gene sequencing may detect a genetic abnormality of clinical significance [
         <a href="#rid49">
          49,50
         </a>
         ]. For example, Noonan syndrome is often associated with polyhydramnios, as well as other abnormalities, and can be diagnosed by gene sequencing. (See
         <a class="medical medical_review" href="/z/d/html/13558.html" rel="external">
          "Noonan syndrome", section on 'Genetic testing'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13558.html" rel="external">
          "Noonan syndrome", section on 'Prenatal testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Consider
         </strong>
         <strong>
          Bartter syndrome
         </strong>
         – In pregnancies with a male fetus and unexplained severe polyhydramnios in the second trimester, especially with previous history of severe polyhydramnios, genetic studies for identification of pathogenic variants in
         <em>
          MAGED2,
         </em>
         which causes antenatal Bartter syndrome, should be offered [
         <a href="#rid37">
          37
         </a>
         ]. Accurate prenatal diagnosis can avoid potentially harmful treatment of preterm infants. (See
         <a class="medical medical_review" href="/z/d/html/2344.html" rel="external">
          "Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations", section on 'Bartter-like phenotype'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Screen for
         </strong>
         <strong>
          maternal
         </strong>
         <strong>
          diabetes
         </strong>
         if not previously performed. (See
         <a class="medical medical_review" href="/z/d/html/6797.html" rel="external">
          "Gestational diabetes mellitus: Screening, diagnosis, and prevention"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Congenital infection may be associated with maternal signs or symptoms of infection and/or fetal abnormalities (eg, hydrops, growth restriction, hepatosplenomegaly, cerebral ventriculomegaly, intracranial and intraabdominal calcifications, hyperechogenic fetal bowel, ascites). In the absence of maternal signs and symptoms or fetal findings (other than polyhydramnios), congenital infection (rubella, cytomegalovirus, toxoplasmosis, syphilis) is an unlikely cause of isolated polyhydramnios and we do not screen for it [
         <a href="#rid19">
          19,51
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1226653638">
         <span class="h1">
          OUTCOME
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many idiopathic cases resolve spontaneously, especially if mild [
         <a href="#rid1">
          1,52,53
         </a>
         ]. Transient cases generally have a benign maternal course, but have been associated with an increased risk for macrosomia [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         In a meta-analysis (12 retrospective studies, 2392 idiopathic cases), the odds of the following outcomes were increased compared with pregnancies with normal AFV: neonatal death OR 8.7, fetal demise OR 7.6, macrosomia OR 2.9, malpresentation OR 2.7, cesarean birth OR 2.3, 5-min Apgar score &lt;7 OR 2.2, neonatal intensive care unit admission OR 1.9 [
         <a href="#rid54">
          54
         </a>
         ]. Limitations of the analysis included lack of subdivision for mild, moderate, or severe cases (although the majority were mild case); some studies included diagnoses from the early-second trimester and others from the third trimester; and different criteria were used for the diagnosis of polyhydramnios. A retrospective study that specifically addressed mild idiopathic polyhydramnios compared 204 such cases with 12,476 cases with normal amniotic fluid volume and demonstrated an increased risk of fetal demise (OR 3.38), 5-minute APGAR score &lt;7 (OR 1.68), and LGA (OR 3.87) [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         Persistent polyhydramnios has been associated with an increased risk of several adverse maternal and newborn outcomes in addition to the poor outcomes related to the associated fetal morphologic abnormalities [
         <a href="#rid56">
          56-59
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maternal respiratory compromise
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prelabor rupture of membranes
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Preterm labor and birth
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fetal malposition
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macrosomia (potentially leading to shoulder dystocia)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Umbilical cord prolapse
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abruption (particularly upon membrane rupture)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Longer second stage of labor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postpartum uterine atony
        </p>
        <p>
        </p>
        <p>
         These complications increase the risk for cesarean birth and admission to a neonatal intensive care unit.
        </p>
        <p>
         Maternal respiratory compromise, fetal malposition, cord prolapse, and postpartum uterine atony are related to uterine overdistention from excessive amniotic fluid volume (AFV).
        </p>
        <p class="headingAnchor" id="H647089950">
         <span class="h2">
          Fetal/newborn prognosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preterm labor and preterm prelabor rupture of membranes can lead to spontaneous preterm birth. Preterm birth in affected pregnancies also may be caused by iatrogenic interventions. (See
         <a class="medical medical_review" href="/z/d/html/4965.html" rel="external">
          "Overview of short-term complications in preterm infants"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5033.html" rel="external">
          "Overview of the long-term complications of preterm birth"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4966.html" rel="external">
          "Preterm birth: Definitions of prematurity, epidemiology, and risk factors for infant mortality"
         </a>
         .)
        </p>
        <p>
         The overall risk of fetal death and neonatal death appears to be increased in pregnancies with polyhydramnios compared with pregnancies with normal amniotic fluid, even after adjusting for confounders, such as congenital anomalies and maternal diabetes [
         <a href="#rid7">
          7,60-64
         </a>
         ]. The relative risk appears to increase with increasing severity of polyhydramnios. The absolute risk of death depends upon the etiology. For example, the combination of a small for gestational age fetus and polyhydramnios has a particularly poor prognosis (including perinatal death) due to the high prevalence of fetal chromosomal and structural abnormalities in this setting [
         <a href="#rid65">
          65,66
         </a>
         ].
        </p>
        <p>
         Idiopathic polyhydramnios has also been associated with an increased risk of neonatal morbidity at term, especially neonatal respiratory morbidity [
         <a href="#rid67">
          67
         </a>
         ]. A study on bronchopulmonary dysplasia (BPD) in preterm infant used a logistic regression model to evaluate different prenatal exposures in 1385 BPD cases and 3142 controls and demonstrated that polyhydramnios may be a clinical indicator of premature infants at increased risk for BPD [
         <a href="#rid68">
          68
         </a>
         ]. These and other adverse sequelae associated with idiopathic polyhydramnios are likely related to underlying etiologies, such as malformations, genetic syndromes, and neurologic disorders, that were not identified before birth [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2287303357">
         <span class="h1">
          MANAGEMENT OF POLYHYDRAMNIOS IN SINGLETON PREGNANCIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of twin pregnancies is reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/6789.html" rel="external">
          "Twin-twin transfusion syndrome: Screening, prevalence, pathophysiology, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6793.html" rel="external">
          "Twin-twin transfusion syndrome: Management and outcome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3858056478">
         <span class="h2">
          Polyhydramnios with an identifiable etiology
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The specific underlying etiology of the polyhydramnios should guide antepartum fetal and maternal surveillance, intrapartum management, and timing of birth. (Refer to topics on specific etiologies.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with severe symptomatic polyhydramnios, management of maternal symptoms is similar to that for patients with idiopathic polyhydramnios. (See
         <a class="local">
          'Additional issues in patients with severe polyhydramnios'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2707366395">
         <span class="h2">
          Idiopathic polyhydramnios
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of idiopathic polyhydramnios depends upon the gestational age, severity, and presence of symptoms.
        </p>
        <p class="headingAnchor" id="H2094657103">
         <span class="h3">
          All patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         We order antepartum fetal monitoring in all patients with idiopathic polyhydramnios:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For mild to moderate polyhydramnios, we obtain a biophysical profile (BPP, including the nonstress test [NST] component) upon diagnosis and then every 1 to 2 weeks until 37 weeks, and then weekly from 37 weeks to birth.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For severe polyhydramnios, we obtain the BPPs (including NST) every week from diagnosis until birth. In interpreting the BPP score, clinicians should be cautious about conclusions of fetal well-being with a borderline score (6/8) since the two points for amniotic fluid volume (AFV) in these cases are not reassuring.
        </p>
        <p>
        </p>
        <p>
         No randomized trials have evaluated whether pregnancies complicated by idiopathic polyhydramnios benefit from any method of antenatal surveillance. Although there are no data to suggest that such assessment decreases perinatal mortality, given the increased risk of fetal mortality in these cases (OR 7.6, 95% CI 2.5-23.4 in a meta-analysis [
         <a href="#rid54">
          54
         </a>
         ]), we order antenatal fetal monitoring tests. The Society for Maternal-Fetal Medicine (SMFM) does not consider antenatal fetal surveillance mandatory in pregnancies with mild idiopathic polyhydramnios and no other indication for surveillance [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H264037132">
         <span class="h3">
          Additional issues in patients without severe polyhydramnios
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients without severe polyhydramnios are not candidates for intervention as they typically do not experience severe symptoms related to polyhydramnios, pregnancy outcome may not be adversely affected, and there are no interventions that improve pregnancy outcome [
         <a href="#rid42">
          42,70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2631508183">
         <span class="h3">
          Additional issues in patients with severe polyhydramnios
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe (amniotic fluid index [AFI] ≥35 cm or single deepest pocket [SDP] ≥16 cm) polyhydramnios may cause maternal shortness of breath, abdominal discomfort, and uterine contractions. The decision to intervene depends on symptom severity. Our approach is discussed below and shown in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef127797" href="/z/d/graphic/127797.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3898613320">
         <span class="h4">
          Asymptomatic patients and patients with mild symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intervention to reduce amniotic fluid is not indicated in asymptomatic patients or patients with mild shortness of breath, abdominal discomfort, and/or uterine irritability that is reasonably tolerable, as pregnancy outcome may not be adversely affected and there are no interventions that improve pregnancy outcome [
         <a href="#rid42">
          42,70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3982713800">
         <span class="h4">
          Patients with severe shortness of breath and/or abdominal discomfort
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with severe polyhydramnios causing severe shortness of breath and/or abdominal discomfort (ie, significantly interfering with the patient's ability to conduct the normal activities of daily life), we suggest decompression amniocentesis (also called amnioreduction) to normalize fluid volume. The goal is to relieve the significant maternal discomfort and avoid iatrogenic preterm birth for maternal indications [
         <a href="#rid70">
          70,71
         </a>
         ]. There is no evidence that the procedure prolongs gestation by reducing the risk of spontaneous preterm labor and birth. We also administer a course of antenatal
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         . The procedure for the initial and subsequent decompression amniocenteses is described below. (See
         <a class="local">
          'Amnioreduction (decompression amniocentesis)'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         No randomized trials have directly compared amnioreduction with expectant management or
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         for management of polyhydramnios. In the largest series of amnioreduction for treatment of polyhydramnios (138 patients), 46 percent of patients required &gt;1 procedure, the median duration from the first procedure until delivery was 26 days, and 4 percent of procedures were associated with unplanned preterm birth within 48 hours, which was the only complication in this series (no cases of chorioamnionitis or abruption) [
         <a href="#rid70">
          70
         </a>
         ]. Although data on symptom relief were not collected, anecdotally, the authors felt that patients typically had a favorable response.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         SMFM recommends considering amnioreduction for relief of severe maternal discomfort, dyspnea, or both in the setting of severe polyhydramnios, and has recommended not using
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         for the sole purpose of decreasing amniotic fluid in these cases because of concerns about medication-related neonatal complications [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1253008206">
         <span class="h4">
          Patients with preterm labor/frequent uterine contractility
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          &lt;32 weeks of gestation and not meeting symptom criteria for amnioreduction
         </strong>
         – For patients with preterm labor or distressing uterine irritability but without severe shortness of breath or abdominal discomfort necessitating amnioreduction, we give a short course (48 hours) of
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         alone to reduce contractile activity and potentially delay birth. An additional advantage of indomethacin is that it may reduce AFV. We also administer a course of antenatal
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         , given the risk of preterm birth.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          &lt;32 weeks of gestation and meeting symptom criteria for amnioreduction
         </strong>
         – For patients &lt;32 weeks who are undergoing amnioreduction because of severe shortness of breath or abdominal discomfort and who have periprocedural uterine contractions, we give a short course (48 hours) of
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         before and/or after the procedure to utilize both its tocolytic and therapeutic effects (reduce the rate of reaccumulation of amniotic fluid and recurrent polyhydramnios). Amnioreduction may also reduce uterine activity [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ≥32 and &lt;34 weeks
         </strong>
         – We do not use
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         to treat preterm labor/bothersome uterine irritability at this gestational age because of the potential for adverse fetal/neonatal effects. We would use another tocolytic (eg,
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         or a beta-2-receptor agonist), if needed, to delay birth and enable a course of antenatal
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ≥34 weeks
         </strong>
         – We do not use any tocolytic to treat preterm labor/bothersome uterine irritability in pregnancies ≥34 weeks of gestation. We would administer an initial course of
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         to pregnancies at 34+0 to 36+6 weeks of gestation at high risk for preterm birth within seven days, according to standard guidelines. (See
         <a class="medical medical_review" href="/z/d/html/6796.html" rel="external">
          "Antenatal corticosteroid therapy for reduction of neonatal respiratory morbidity and mortality from preterm delivery", section on '34+0 or more weeks'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          Indomethacin
         </a>
         dosing and side effects are discussed below. (See
         <a class="local">
          'Indomethacin'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2213154501">
         <span class="h5">
          Refractory symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amnioreduction should relieve maternal symptoms immediately, but amniotic fluid can reaccumulate within a few days to weeks.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          &lt;34 weeks of gestation
         </strong>
         – For patients with severe symptoms due to recurrent polyhydramnios after an initial amnioreduction, we repeat amnioreduction. We also consider, on a case-by-case basis, another short course (48 hours) of
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         for those &lt;32 weeks with persistent uterine irritability to take advantage of its favorable effects on both uterine activity and AFV in this setting [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ≥34 weeks of gestation
         </strong>
         – For patients with severe symptomatic polyhydramnios ≥34 weeks in whom amnioreduction has been unsuccessful because of rapid reaccumulation of fluid, we discuss preterm birth for relief of maternal discomfort and make this shared decision on a case-by-case basis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3847027567">
         <span class="h3">
          Amnioreduction (decompression amniocentesis)
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no consensus about how much amniotic fluid to remove, how rapidly to remove the fluid, or use of tocolytic medications and antibiotics. We do not use antibiotic prophylaxis and only initiate
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         as a tocolytic in patients with contractions.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Technique
         </strong>
         – A
         <strong>
         </strong>
         common
         <strong>
         </strong>
         technique is to:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cleanse the site with a surgical scrub and then administer local anesthesia into the skin and subcuticular tissues.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Under continuous ultrasound guidance to minimize fetal contact, insert an 18-gauge needle with the tip directed toward the fluid. It is often useful to insert the needle in a caudal direction with the hub of the needle positioned cranially so the needle can be advanced as the uterus becomes smaller with decompression.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Attach hard-walled arterial line tubing with a three-way stopcock to the needle and connect to a vacuum suction bottle. The fluid may be suctioned directly into the container or, alternatively, removed with a 50 mL syringe under controlled suction, but this can be tedious when there is a lot of fluid.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A reasonable guideline is to remove no more than 2.0 to 2.5 liters at one time and to remove the fluid no faster than 1000 mL over 20 minutes, although rates of 100 to 125 mL/minute have been reported [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Terminate the procedure when the AFV is normalized (generally AFI 15 to 20 cm or maximum vertical pocket &lt;8 cm) [
         <a href="#rid39">
          39
         </a>
         ]. Sometimes, the procedure will need to be terminated early because of patient discomfort, a clogged needle, or membrane separation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications
         </strong>
         – Complication rates in small series are generally low, ranging from 1 to 10 percent of procedures. Complications include preterm labor and prelabor rupture of membranes, which are the most common complications, and less commonly abruption, intraamniotic infection, and hypoproteinemia [
         <a href="#rid70">
          70,71,73,74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postprocedure follow-up
         </strong>
         – Following amnioreduction, we monitor AFV every one to three weeks as indicated by the progression and severity of the amniotic fluid reaccumulation process.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Repeat procedures
         </strong>
         – Repeat procedures can be performed at any interval. On average, two procedures at least a week apart are needed to reduce AFV chronically, although some patients require many more procedures [
         <a href="#rid71">
          71,73
         </a>
         ]. One unusual case report described 12 amnioreductions over 12 weeks that removed a total of 21,600 mL of fluid; the infant was diagnosed with West syndrome at follow-up 16 months after birth [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2136983543">
         <span class="h3">
          Indomethacin
         </span>
         <span class="headingEndMark">
          —
         </span>
         SMFM recommends not administering
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         for the sole indication of reducing amniotic fluid [
         <a href="#rid42">
          42
         </a>
         ]. As noted above, in pregnancies &lt;32 weeks of gestation with preterm labor/uterine irritability, we sometimes use a short course (48 hours) of indomethacin for its combined effects of tocolysis and reduction in AFV. Adverse fetal effects, including premature closure of the ductus arteriosus and renal impairment, are a concern when the drug is used for ≥3 days and when it is used at ≥30 weeks. (See
         <a class="local">
          'Patients with preterm labor/frequent uterine contractility'
         </a>
         above and
         <a class="local">
          'Refractory symptoms'
         </a>
         above.)
        </p>
        <p>
         Maternal administration of prostaglandin synthetase inhibitors reduces AFV in pregnancies with normal or abnormal AFV at baseline. These drugs may stimulate fetal secretion of arginine vasopressin and facilitate vasopressin-induced renal antidiuretic responses and reduce renal blood flow, thereby reducing fetal urine flow. They also may impair production or enhance reabsorption of lung liquid [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – Various
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         regimens have been used, but a common approach is an initial dose of 25 mg orally four times daily and limiting treatment to pregnancies &lt;32 weeks and to a short course (48 hours) of therapy [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Maternal and fetal side effects
         </strong>
         – Maternal side effects, such as nausea, esophageal reflux, gastritis, and emesis, have been studied primarily in patients receiving the drug for inhibition of preterm labor; the prevalence of side effects in this population is 4 percent. Platelet dysfunction may occur. Alterations in maternal cardiovascular physiology are minimal. (See
         <a class="medical medical_review" href="/z/d/html/7991.html" rel="external">
          "Nonselective NSAIDs: Overview of adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The primary fetal concern with use of
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         is constriction of the ductus arteriosus. This side effect is more likely when the duration of indomethacin exposure exceeds 72 hours and when gestational age is ≥32 weeks. Prolonged indomethacin use may also result in oligohydramnios and fetal/neonatal renal impairment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other possible fetal adverse effects include neonatal necrotizing enterocolitis and intraventricular hemorrhage, but these associations are more controversial. Effects of
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         on the fetus/neonate are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6742.html" rel="external">
          "Inhibition of acute preterm labor", section on 'Fetal side effects'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Labor management
         </span>
         <span class="headingEndMark">
          —
         </span>
         During labor, we check fetal position frequently to confirm maintenance of cephalic presentation. The excess amniotic fluid allows greater fetal mobility, so conversion to a breech, compound, or transverse presentation may occur. The fetal heart rate is monitored continuously as these pregnancies are at increased risk of abnormalities [
         <a href="#rid77">
          77,78
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H101229624">
         <span class="h3">
          Membrane rupture
         </span>
         <span class="headingEndMark">
          —
         </span>
         Spontaneous rupture of membranes can cause sudden severe uterine decompression with risk of cord prolapse or abruption. Prophylactic gradual abdominal or transcervical amnioreduction with a needle when the head is engaged may prevent these complications during labor. The risk of cord prolapse should be considered if membrane rupture at high station is being contemplated solely for uterine decompression. Controlled amniotomy in the operating room is performed by using a small gauge needle to puncture the fetal membranes in one or more places, while a second operator is stabilizing the fetus in longitudinal lie/cephalic presentation. This minimizes the risk of gushing amniotic fluid and allows for rapid cesarean birth in the event of cord prolapse. Similarly, the amniotomy should be performed between, not during, uterine contractions, if possible.
        </p>
        <p class="headingAnchor" id="H3656550016">
         <span class="h2">
          Timing of delivery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although there is no absolute contraindication to use of
         <a class="drug drug_general" data-topicid="9734" href="/z/d/drug information/9734.html" rel="external">
          oxytocin
         </a>
         or prostaglandins for cervical ripening and labor induction in patients with polyhydramnios, these drugs should be used with caution. There is a marked increase in the incidence of postpartum hemorrhage related to atony in patients with polyhydramnios; use of uterine stimulants may increase this risk and that of amniotic fluid embolism [
         <a href="#rid76">
          76,79
         </a>
         ]. However, we use prostaglandins for cervical ripening and oxytocin for induction, as clinically indicated. (See
         <a class="medical medical_review" href="/z/d/html/5398.html" rel="external">
          "Induction of labor: Techniques for preinduction cervical ripening"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4476.html" rel="external">
          "Induction of labor with oxytocin"
         </a>
         .)
        </p>
        <p>
         Timing of delivery is influenced by the underlying etiology and the severity of polyhydramnios:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild to moderate polyhydramnios
         </strong>
         – In patients with mild to moderate idiopathic polyhydramnios  (
         <a class="graphic graphic_table graphicRef89351" href="/z/d/graphic/89351.html" rel="external">
          table 2
         </a>
         ) and normal BPPs, we induce labor at 39+0 to 40+0 weeks of gestation as the risk of fetal death appears to increase significantly at term [
         <a href="#rid64">
          64
         </a>
         ]. The American College of Obstetricians and Gynecologists/SMFM recommends birth at 39+0 to 40+6 weeks for patients with mild idiopathic polyhydramnios [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe polyhydramnios
         </strong>
         – In patients with severe idiopathic polyhydramnios, we offer induction of labor at 37+0 weeks to minimize the risk of umbilical cord prolapse and/or abruption in the event of spontaneous prelabor rupture of membranes. We offer earlier delivery on a case-by-case basis to patients between 34+0 and 37+0 weeks whose symptoms are intolerable and who have not responded to amnioreduction procedures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Delivery at a tertiary center is recommended for patients with severe idiopathic polyhydramnios since clinically important fetal abnormalities may not have been identified prenatally.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3469915881">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/127024.html" rel="external">
          "Society guideline links: Oligohydramnios and polyhydramnios"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathogenesis and etiology
         </strong>
         – Polyhydramnios may be idiopathic or associated with a variety of fetal disorders  (
         <a class="graphic graphic_table graphicRef130889" href="/z/d/graphic/130889.html" rel="external">
          table 1
         </a>
         ). Decreased fetal swallowing or increased fetal urination is often the underlying mechanism for increased amniotic fluid volume (AFV). The most common associated conditions are fetal malformations and/or genetic disorders, maternal diabetes mellitus, multiple gestation, and fetal anemia. Bartter syndrome is a rare cause. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above and
         <a class="local">
          'Conditions associated with polyhydramnios'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – In patients with a qualitative impression of polyhydramnios, we suggest performing a quantitative measurement. We use single deepest pocket (SDP) ≥8 cm or amniotic fluid index (AFI) ≥24 cm to define polyhydramnios. Quantitative indices are standardized and provide a measurement that can be followed on serial examinations, even though sensitivity and positive predictive value are suboptimal. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postdiagnostic evaluation
         </strong>
         (see
         <a class="local">
          'Postdiagnostic evaluation'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Detailed sonographic evaluation to look for fetal anomalies and/or hydrops
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Laboratory evaluations depend upon sonographic findings and may include screening for gestational diabetes, testing for fetomaternal hemorrhage if fetal anemia is suspected, maternal serology to determine exposure to infectious agents (eg, syphilis, parvovirus, cytomegalovirus, toxoplasmosis, rubella), and appropriate tests for hereditary anemias (eg, alpha-thalassemia) or inborn errors of metabolism. (See
         <a class="local">
          'Postdiagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We offer fetal microarray analysis in cases of severe polyhydramnios or if there are associated anatomic anomalies, especially if the results will affect management. Amniotic fluid biochemical analyses can help in the diagnosis of esophageal atresia and Bartter syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcome
         </strong>
         – The outcome of pregnancies complicated by polyhydramnios varies according to the severity and underlying etiology of the excessive fluid accumulation. Possible complications include maternal respiratory compromise, preterm labor, prelabor rupture of membranes, fetal malposition, abruption, umbilical cord prolapse, fetal or neonatal death, and/or postpartum uterine atony. (See
         <a class="local">
          'Outcome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial management
         </strong>
         – We limit treatment of idiopathic polyhydramnios to singleton pregnancies with severe polyhydramnios (AFI ≥35 cm or SDP ≥16 cm) and severe symptoms (ie, significantly interfering with the patient's ability to conduct the normal activities of daily life).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For asymptomatic patients or patients with mild shortness of breath, abdominal discomfort, and/or uterine irritability that is reasonably tolerable, we suggest avoiding intervention to reduce amniotic fluid (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Asymptomatic patients and patients with mild symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with severe polyhydramnios causing significant shortness of breath and/or abdominal discomfort, we suggest amnioreduction (decompression amniocentesis) rather than
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         to normalize fluid volume (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Indomethacin can have adverse fetal effects. We also administer a course of antenatal
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         . (See
         <a class="local">
          'Patients with severe shortness of breath and/or abdominal discomfort'
         </a>
         above and
         <a class="local">
          'Indomethacin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients &lt;32 weeks who are undergoing amnioreduction and have periprocedural uterine contractions, we suggest a short course (48 hours) of
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         before and/or after the procedure (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This utilizes both its tocolytic and therapeutic effects (reduces the rate of reaccumulation of amniotic fluid and recurrent polyhydramnios). (See
         <a class="local">
          'Patients with preterm labor/frequent uterine contractility'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients &lt;32 weeks with severe polyhydramnios and preterm labor/bothersome uterine irritability but without significant shortness of breath or abdominal discomfort necessitating amnioreduction, we suggest a short course (48 hours) of
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         alone to reduce contractile activity and potentially delay delivery (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). An additional advantage of indomethacin is that it may reduce amniotic fluid volume (AFV). We also administer a course of antenatal
         <a class="drug drug_general" data-topicid="9139" href="/z/d/drug information/9139.html" rel="external">
          betamethasone
         </a>
         given the risk of preterm birth. (See
         <a class="local">
          'Patients with preterm labor/frequent uterine contractility'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of refractory idiopathic polyhydramnios
         </strong>
         (see
         <a class="local">
          'Refractory symptoms'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients &lt;34 weeks with severe symptoms due to recurrent polyhydramnios after an initial amnioreduction, we perform repeat amnioreduction and consider, on a case-by-case basis, another short course (48 hours) of
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         to those &lt;32 weeks with persistent uterine irritability to take advantage of its favorable effects on both uterine activity and AFV in this setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with severe symptomatic polyhydramnios at ≥34 weeks in whom amnioreduction has been unsuccessful because of reaccumulation of fluid, we discuss preterm delivery for relief of maternal discomfort and make this shared decision on a case-by-case basis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing of delivery
         </strong>
         – We deliver patients with mild idiopathic polyhydramnios 39+0 to 40+0 weeks. Timing in other cases depends on the etiology and severity. (See
         <a class="local">
          'Timing of delivery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intrapartum management
         </strong>
         – During labor, fetal position should be checked frequently as the excess amniotic fluid allows greater fetal mobility, so conversion to a breech, compound, or transverse presentation may occur. Spontaneous rupture of membranes can cause sudden severe uterine decompression with risk of cord prolapse or abruption. Prophylactic gradual abdominal or transcervical amnioreduction with a needle when the head is engaged may prevent these complications during labor. (See
         <a class="local">
          'Labor management'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Golan A, Wolman I, Sagi J, et al. Persistence of polyhydramnios during pregnancy--its significance and correlation with maternal and fetal complications. Gynecol Obstet Invest 1994; 37:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Many A, Hill LM, Lazebnik N, Martin JG. The association between polyhydramnios and preterm delivery. Obstet Gynecol 1995; 86:389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith CV, Plambeck RD, Rayburn WF, Albaugh KJ. Relation of mild idiopathic polyhydramnios to perinatal outcome. Obstet Gynecol 1992; 79:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill LM, Breckle R, Thomas ML, Fries JK. Polyhydramnios: ultrasonically detected prevalence and neonatal outcome. Obstet Gynecol 1987; 69:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dashe JS, McIntire DD, Ramus RM, et al. Hydramnios: anomaly prevalence and sonographic detection. Obstet Gynecol 2002; 100:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson O, Brown R, Gunnarson G, Harrington K. Prevalence of polyhydramnios in the third trimester in a population screened by first and second trimester ultrasonography. J Perinat Med 1998; 26:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Biggio JR Jr, Wenstrom KD, Dubard MB, Cliver SP. Hydramnios prediction of adverse perinatal outcome. Obstet Gynecol 1999; 94:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pri-Paz S, Khalek N, Fuchs KM, Simpson LL. Maximal amniotic fluid index as a prognostic factor in pregnancies complicated by polyhydramnios. Ultrasound Obstet Gynecol 2012; 39:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauserman M, Nathan R, Lokangaka A, et al. Polyhydramnios among women in a cluster-randomized trial of ultrasound during prenatal care within five low and low-middle income countries: a secondary analysis of the first look study. BMC Pregnancy Childbirth 2019; 19:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harding R, Bocking AD, Sigger JN, Wickham PJ. Composition and volume of fluid swallowed by fetal sheep. Q J Exp Physiol 1984; 69:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           PRITCHARD JA. DEGLUTITION BY NORMAL AND ANENCEPHALIC FETUSES. Obstet Gynecol 1965; 25:289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritchard JA. Fetal swallowing and amniotic fluid volume. Obstet Gynecol 1966; 28:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maymon R, Strauss S, Herman A, et al. The prenatal scan pitfall for the diagnosis of renal mass: case report. Prenat Diagn 2004; 24:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu YC, Mai YL, Chang CC, et al. The presence of hydrops fetalis in a fetus with congenital mesoblastic nephroma. Prenat Diagn 1996; 16:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abele H, Starz S, Hoopmann M, et al. Idiopathic polyhydramnios and postnatal abnormalities. Fetal Diagn Ther 2012; 32:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dorleijn DM, Cohen-Overbeek TE, Groenendaal F, et al. Idiopathic polyhydramnios and postnatal findings. J Matern Fetal Neonatal Med 2009; 22:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Touboul C, Boileau P, Picone O, et al. Outcome of children born out of pregnancies complicated by unexplained polyhydramnios. BJOG 2007; 114:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Touboul C, Picone O, Levaillant JM, et al. Clinical application of fetal urine production rate in unexplained polyhydramnios. Ultrasound Obstet Gynecol 2009; 34:521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasquini L, Seravalli V, Sisti G, et al. Prevalence of a positive TORCH and parvovirus B19 screening in pregnancies complicated by polyhydramnios. Prenat Diagn 2016; 36:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rasmussen S, Linde LE, Ebbing C. Recurrence of idiopathic polyhydramnios: A nationwide population study. Int J Gynaecol Obstet 2022; 157:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Chetrit A, Hochner-Celnikier D, Ron M, Yagel S. Hydramnios in the third trimester of pregnancy: a change in the distribution of accompanying fetal anomalies as a result of early ultrasonographic prenatal diagnosis. Am J Obstet Gynecol 1990; 162:1344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoll CG, Alembik Y, Dott B. Study of 156 cases of polyhydramnios and congenital malformations in a series of 118,265 consecutive births. Am J Obstet Gynecol 1991; 165:586.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore LE. Amount of polyhydramnios attributable to diabetes may be less than previously reported. World J Diabetes 2017; 8:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bicocca MJ, Qureshey EJ, Chauhan SP, et al. Semiquantitative Assessment of Amniotic Fluid Among Individuals With and Without Diabetes Mellitus. J Ultrasound Med 2022; 41:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vink JY, Poggi SH, Ghidini A, Spong CY. Amniotic fluid index and birth weight: is there a relationship in diabetics with poor glycemic control? Am J Obstet Gynecol 2006; 195:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Idris N, Wong SF, Thomae M, et al. Influence of polyhydramnios on perinatal outcome in pregestational diabetic pregnancies. Ultrasound Obstet Gynecol 2010; 36:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crimmins S, Mo C, Nassar Y, et al. Polyhydramnios or Excessive Fetal Growth Are Markers for Abnormal Perinatal Outcome in Euglycemic Pregnancies. Am J Perinatol 2018; 35:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walter A, Calite E, Berg C, et al. Prenatal diagnosis of fetal growth restriction with polyhydramnios, etiology and impact on postnatal outcome. Sci Rep 2022; 12:415.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagi-Dain L, Singer A, Falik-Zaccai T, et al. The effect of polyhydramnios degree on chromosomal microarray results: a retrospective cohort analysis of 742 singleton pregnancies. Arch Gynecol Obstet 2021; 304:649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sieck UV, Ohlsson A. Fetal polyuria and hydramnios associated with Bartter's syndrome. Obstet Gynecol 1984; 63:22S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Upadhyay K, Thomson A, Luckas MJ. Congenital myotonic dystrophy. Fetal Diagn Ther 2005; 20:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaki M, Boyd PA, Impey L, et al. Congenital myotonic dystrophy: prenatal ultrasound findings and pregnancy outcome. Ultrasound Obstet Gynecol 2007; 29:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geifman-Holtzman O, Fay K. Prenatal diagnosis of congenital myotonic dystrophy and counseling of the pregnant mother: case report and literature review. Am J Med Genet 1998; 78:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rogers R, Moyer K, Moise KJ Jr. Congenital myotonic dystrophy: An overlooked diagnosis not amenable to detection by sequencing. Prenat Diagn 2022; 42:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yee C, Choi SJ, Oh SY, et al. Clinical characteristics of pregnancies complicated by congenital myotonic dystrophy. Obstet Gynecol Sci 2017; 60:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weissbach T, Hausman-Kedem M, Yanay Z, et al. Congenital hypotonia: systematic approach for prenatal detection. Ultrasound Obstet Gynecol 2023; 62:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laghmani K, Beck BB, Yang SS, et al. Polyhydramnios, Transient Antenatal Bartter's Syndrome, and MAGED2 Mutations. N Engl J Med 2016; 374:1853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma GC, Chen TH, Wu WJ, et al. Proposal for Practical Approach in Prenatal Diagnosis of Beckwith-Wiedemann Syndrome and Review of the Literature. Diagnostics (Basel) 2022; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fisk NM, Tannirandorn Y, Nicolini U, et al. Amniotic pressure in disorders of amniotic fluid volume. Obstet Gynecol 1990; 76:210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katsura D, Takahashi Y, Iwagaki S, et al. Relationship between higher intra-amniotic pressures in polyhydramnios and maternal symptoms. Eur J Obstet Gynecol Reprod Biol 2019; 235:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reddy UM, Abuhamad AZ, Levine D, et al. Fetal imaging: executive summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society for Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging workshop. Obstet Gynecol 2014; 123:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Society for Maternal-Fetal Medicine (SMFM). Electronic address:
           <span class="__cf_email__" data-cfemail="235356415063504e454e0d4c5144">
            [email protected]
           </span>
           , Dashe JS, Pressman EK, Hibbard JU. SMFM Consult Series #46: Evaluation and management of polyhydramnios. Am J Obstet Gynecol 2018; 219:B2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes DS, Magann EF, Whittington JR, et al. Accuracy of the Ultrasound Estimate of the Amniotic Fluid Volume (Amniotic Fluid Index and Single Deepest Pocket) to Identify Actual Low, Normal, and High Amniotic Fluid Volumes as Determined by Quantile Regression. J Ultrasound Med 2020; 39:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Czerkiewicz I, Dreux S, Beckmezian A, et al. Biochemical amniotic fluid pattern for prenatal diagnosis of esophageal atresia. Pediatr Res 2011; 70:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mari G, Deter RL, Carpenter RL, et al. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. N Engl J Med 2000; 342:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimmerman R, Carpenter RJ Jr, Durig P, Mari G. Longitudinal measurement of peak systolic velocity in the fetal middle cerebral artery for monitoring pregnancies complicated by red cell alloimmunisation: a prospective multicentre trial with intention-to-treat. BJOG 2002; 109:746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrei C, Vladareanu R. The value of reference ranges for middle cerebral artery peak systolic velocity in the management of rhesus alloimmunized pregnancies. Maedica (Bucur) 2012; 7:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kornacki J, Adamczyk M, Wirstlein P, et al. Polyhydramnios - frequency of congenital anomalies in relation to the value of the amniotic fluid index. Ginekol Pol 2017; 88:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamouroux A, Mousty E, Prodhomme O, et al. [Absent or hypoplastic thymus: A marker for 22q11.2 microdeletion syndrome in case of polyhydramnios]. J Gynecol Obstet Biol Reprod (Paris) 2016; 45:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boito S, Crovetto F, Ischia B, et al. Prenatal ultrasound factors and genetic disorders in pregnancies complicated by polyhydramnios. Prenat Diagn 2016; 36:726.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fayyaz H, Rafi J. TORCH screening in polyhydramnios: an observational study. J Matern Fetal Neonatal Med 2012; 25:1069.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odibo IN, Newville TM, Ounpraseuth ST, et al. Idiopathic polyhydramnios: persistence across gestation and impact on pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol 2016; 199:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wax JR, Cartin A, Craig WY, Pinette MG. Transient Idiopathic Polyhydramnios: Maternal and Perinatal Outcomes: Maternal and Perinatal Outcomes. J Ultrasound Med 2022; 41:2859.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagan M, Magann EF, Rabie N, et al. Idiopathic polyhydramnios and pregnancy outcome: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2023; 61:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pagan M, Strebeck R, Dajani N, et al. Title: Is Mild Idiopathic Polyhydramnios Associated with an Increased Risk for an Intrauterine Fetal Demise? A Retrospective Cohort Study. Int J Womens Health 2023; 15:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross MG, Brace RA, National Institute of Child Health and Development Workshop Participants. National Institute of Child Health and Development Conference summary: amniotic fluid biology--basic and clinical aspects. J Matern Fetal Med 2001; 10:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karahanoglu E, Ozdemirci S, Esinler D, et al. Intrapartum, postpartum characteristics and early neonatal outcomes of idiopathic polyhydramnios. J Obstet Gynaecol 2016; 36:710.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiegand SL, Beamon CJ, Chescheir NC, Stamilio D. Idiopathic Polyhydramnios: Severity and Perinatal Morbidity. Am J Perinatol 2016; 33:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khazaei S, Jenabi E. The association between polyhydramnios and the risk of placenta abruption: a meta-analysis. J Matern Fetal Neonatal Med 2020; 33:3035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magann EF, Chauhan SP, Doherty DA, et al. A review of idiopathic hydramnios and pregnancy outcomes. Obstet Gynecol Surv 2007; 62:795.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maymon E, Ghezzi F, Shoham-Vardi I, et al. Isolated hydramnios at term gestation and the occurrence of peripartum complications. Eur J Obstet Gynecol Reprod Biol 1998; 77:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazor M, Ghezzi F, Maymon E, et al. Polyhydramnios is an independent risk factor for perinatal mortality and intrapartum morbidity in preterm delivery. Eur J Obstet Gynecol Reprod Biol 1996; 70:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panting-Kemp A, Nguyen T, Chang E, et al. Idiopathic polyhydramnios and perinatal outcome. Am J Obstet Gynecol 1999; 181:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pilliod RA, Page JM, Burwick RM, et al. The risk of fetal death in nonanomalous pregnancies affected by polyhydramnios. Am J Obstet Gynecol 2015; 213:410.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Erez O, Shoham-Vardi I, Sheiner E, et al. Hydramnios and small for gestational age are independent risk factors for neonatal mortality and maternal morbidity. Arch Gynecol Obstet 2005; 271:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sickler GK, Nyberg DA, Sohaey R, Luthy DA. Polyhydramnios and fetal intrauterine growth restriction: ominous combination. J Ultrasound Med 1997; 16:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polnaszek B, Liang B, Zhang F, et al. Idiopathic Polyhydramnios and Neonatal Morbidity at Term. Am J Perinatol 2023; 40:1827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell MS, Bastarache LA, Van Driest SL, et al. Bronchopulmonary dysplasia is associated with polyhydramnios in a scan for novel perinatal risk factors. Pediatr Res 2023; 93:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yefet E, Daniel-Spiegel E. Outcomes From Polyhydramnios With Normal Ultrasound. Pediatrics 2016; 137:e20151948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickinson JE, Tjioe YY, Jude E, et al. Amnioreduction in the management of polyhydramnios complicating singleton pregnancies. Am J Obstet Gynecol 2014; 211:434.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elliott JP, Sawyer AT, Radin TG, Strong RE. Large-volume therapeutic amniocentesis in the treatment of hydramnios. Obstet Gynecol 1994; 84:1025.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jauniaux E, Holmes A, Hyett J, et al. Rapid and radical amniodrainage in the treatment of severe twin-twin transfusion syndrome. Prenat Diagn 2001; 21:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung WC, Jouannic JM, Hyett J, et al. Procedure-related complications of rapid amniodrainage in the treatment of polyhydramnios. Ultrasound Obstet Gynecol 2004; 23:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soni S, Paidas Teefey C, Gebb JS, et al. Amnioreduction vs expectant management in pregnancies with moderate to severe polyhydramnios. Am J Obstet Gynecol MFM 2023; 5:101192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer WB, Van den Veyver IB, Kirshon B. Treatment of polyhydramnios with indomethacin. Clin Perinatol 1994; 21:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harman CR. Amniotic fluid abnormalities. Semin Perinatol 2008; 32:288.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aviram A, Salzer L, Hiersch L, et al. Association of isolated polyhydramnios at or beyond 34 weeks of gestation and pregnancy outcome. Obstet Gynecol 2015; 125:825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khan S, Donnelly J. Outcome of pregnancy in women diagnosed with idiopathic polyhydramnios. Aust N Z J Obstet Gynaecol 2017; 57:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer MS, Rouleau J, Baskett TF, et al. Amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study. Lancet 2006; 368:1444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American College of Obstetricians and Gynecologists’ Committee on Obstetric Practice, Society for Maternal-Fetal Medicine. Medically Indicated Late-Preterm and Early-Term Deliveries: ACOG Committee Opinion, Number 831. Obstet Gynecol 2021; 138:e35.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6781 Version 60.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8125402" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Persistence of polyhydramnios during pregnancy--its significance and correlation with maternal and fetal complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7651648" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The association between polyhydramnios and preterm delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1738520" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Relation of mild idiopathic polyhydramnios to perinatal outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3540761" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Polyhydramnios: ultrasonically detected prevalence and neonatal outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12100815" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Hydramnios: anomaly prevalence and sonographic detection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10027132" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Prevalence of polyhydramnios in the third trimester in a population screened by first and second trimester ultrasonography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10546727" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Hydramnios prediction of adverse perinatal outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21898637" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Maximal amniotic fluid index as a prognostic factor in pregnancies complicated by polyhydramnios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31331296" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Polyhydramnios among women in a cluster-randomized trial of ultrasound during prenatal care within five low and low-middle income countries: a secondary analysis of the first look study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6473692" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Composition and volume of fluid swallowed by fetal sheep.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14268007" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : DEGLUTITION BY NORMAL AND ANENCEPHALIC FETUSES.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5332288" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Fetal swallowing and amniotic fluid volume.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15565594" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The prenatal scan pitfall for the diagnosis of renal mass: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8734816" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The presence of hydrops fetalis in a fetus with congenital mesoblastic nephroma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22760013" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Idiopathic polyhydramnios and postnatal abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19085623" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Idiopathic polyhydramnios and postnatal findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17309542" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Outcome of children born out of pregnancies complicated by unexplained polyhydramnios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19830790" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Clinical application of fetal urine production rate in unexplained polyhydramnios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26970557" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prevalence of a positive TORCH and parvovirus B19 screening in pregnancies complicated by polyhydramnios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34719034" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Recurrence of idiopathic polyhydramnios: A nationwide population study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2187359" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Hydramnios in the third trimester of pregnancy: a change in the distribution of accompanying fetal anomalies as a result of early ultrasonographic prenatal diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1892183" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Study of 156 cases of polyhydramnios and congenital malformations in a series of 118,265 consecutive births.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28138359" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Amount of polyhydramnios attributable to diabetes may be less than previously reported.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33885190" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Semiquantitative Assessment of Amniotic Fluid Among Individuals With and Without Diabetes Mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16949424" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Amniotic fluid index and birth weight: is there a relationship in diabetics with poor glycemic control?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20503236" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Influence of polyhydramnios on perinatal outcome in pregestational diabetic pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28838004" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Polyhydramnios or Excessive Fetal Growth Are Markers for Abnormal Perinatal Outcome in Euglycemic Pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35013541" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Prenatal diagnosis of fetal growth restriction with polyhydramnios, etiology and impact on postnatal outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33591382" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The effect of polyhydramnios degree on chromosomal microarray results: a retrospective cohort analysis of 742 singleton pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6366663" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Fetal polyuria and hydramnios associated with Bartter's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16260886" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Congenital myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17238150" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Congenital myotonic dystrophy: prenatal ultrasound findings and pregnancy outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9677060" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Prenatal diagnosis of congenital myotonic dystrophy and counseling of the pregnant mother: case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35083764" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Congenital myotonic dystrophy: An overlooked diagnosis not amenable to detection by sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28791262" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Clinical characteristics of pregnancies complicated by congenital myotonic dystrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36779229" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Congenital hypotonia: systematic approach for prenatal detection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27120771" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Polyhydramnios, Transient Antenatal Bartter's Syndrome, and MAGED2 Mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35885613" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Proposal for Practical Approach in Prenatal Diagnosis of Beckwith-Wiedemann Syndrome and Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2196499" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Amniotic pressure in disorders of amniotic fluid volume.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30797177" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Relationship between higher intra-amniotic pressures in polyhydramnios and maternal symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24785860" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Fetal imaging: executive summary of a joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society for Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging workshop.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30048635" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : SMFM Consult Series #46: Evaluation and management of polyhydramnios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31423632" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Accuracy of the Ultrasound Estimate of the Amniotic Fluid Volume (Amniotic Fluid Index and Single Deepest Pocket) to Identify Actual Low, Normal, and High Amniotic Fluid Volumes as Determined by Quantile Regression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21522036" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Biochemical amniotic fluid pattern for prenatal diagnosis of esophageal atresia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10620643" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12135209" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Longitudinal measurement of peak systolic velocity in the fetal middle cerebral artery for monitoring pregnancies complicated by red cell alloimmunisation: a prospective multicentre trial with intention-to-treat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23118814" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : The value of reference ranges for middle cerebral artery peak systolic velocity in the management of rhesus alloimmunized pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28930371" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Polyhydramnios - frequency of congenital anomalies in relation to the value of the amniotic fluid index.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26096354" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : [Absent or hypoplastic thymus: A marker for 22q11.2 microdeletion syndrome in case of polyhydramnios].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27247190" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Prenatal ultrasound factors and genetic disorders in pregnancies complicated by polyhydramnios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21923307" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : TORCH screening in polyhydramnios: an observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26937648" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Idiopathic polyhydramnios: persistence across gestation and impact on pregnancy outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35312096" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Transient Idiopathic Polyhydramnios: Maternal and Perinatal Outcomes: Maternal and Perinatal Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35723677" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Idiopathic polyhydramnios and pregnancy outcome: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36756184" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Title: Is Mild Idiopathic Polyhydramnios Associated with an Increased Risk for an Intrauterine Fetal Demise? A Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11332413" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : National Institute of Child Health and Development Conference summary: amniotic fluid biology--basic and clinical aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26926000" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Intrapartum, postpartum characteristics and early neonatal outcomes of idiopathic polyhydramnios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26862725" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Idiopathic Polyhydramnios: Severity and Perinatal Morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30624999" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The association between polyhydramnios and the risk of placenta abruption: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18005456" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : A review of idiopathic hydramnios and pregnancy outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9578272" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Isolated hydramnios at term gestation and the occurrence of peripartum complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9031919" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Polyhydramnios is an independent risk factor for perinatal mortality and intrapartum morbidity in preterm delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10561621" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Idiopathic polyhydramnios and perinatal outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25981851" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The risk of fetal death in nonanomalous pregnancies affected by polyhydramnios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15243757" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Hydramnios and small for gestational age are independent risk factors for neonatal mortality and maternal morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9321781" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Polyhydramnios and fetal intrauterine growth restriction: ominous combination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34775584" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Idiopathic Polyhydramnios and Neonatal Morbidity at Term.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35393523" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Bronchopulmonary dysplasia is associated with polyhydramnios in a scan for novel perinatal risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26755694" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Outcomes From Polyhydramnios With Normal Ultrasound.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24881825" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Amnioreduction in the management of polyhydramnios complicating singleton pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7970458" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Large-volume therapeutic amniocentesis in the treatment of hydramnios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11438952" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Rapid and radical amniodrainage in the treatment of severe twin-twin transfusion syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14770396" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Procedure-related complications of rapid amniodrainage in the treatment of polyhydramnios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37858792" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Amnioreduction vs expectant management in pregnancies with moderate to severe polyhydramnios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7982337" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Treatment of polyhydramnios with indomethacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18652930" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Amniotic fluid abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25751210" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Association of isolated polyhydramnios at or beyond 34 weeks of gestation and pregnancy outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28251633" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Outcome of pregnancy in women diagnosed with idiopathic polyhydramnios.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17055946" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34259491" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Medically Indicated Late-Preterm and Early-Term Deliveries: ACOG Committee Opinion, Number 831.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
